Mitochondrial dysfunctions in cancer: Genetic defects and oncogenic signaling impinging on TCA cycle activity

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 217-223

  Desideri, Enrico ^a   Vegliante, Rolando ^a   Ciriolo, Maria Rosa ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Aconitase; Fumarate hydratase; HIF; Isocitrate dehydrogenase; P53; Succinate dehydrogenase

Indexed keywords

ACONITATE HYDRATASE; FUMARATE HYDRATASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE; MALATE DEHYDROGENASE (DECARBOXYLATING); PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN P53; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE KINASE 1; SUCCINATE DEHYDROGENASE; UNCLASSIFIED DRUG; HIF1A PROTEIN, HUMAN; MALATE DEHYDROGENASE; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE;

AEROBIC METABOLISM; CARCINOGENESIS; CITRIC ACID CYCLE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EPIGENETICS; GENETIC DISORDER; GERMLINE MUTATION; HUMAN; HYPOXIA; MALIGNANT NEOPLASTIC DISEASE; METABOLIC REGULATION; NONHUMAN; ONCOGENE; OXIDATION REDUCTION STATE; P53 GENE; SHORT SURVEY; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; CELL PROLIFERATION; ENERGY METABOLISM; GENETICS; METABOLISM; MITOCHONDRION; MUTATION; NEOPLASM; OXIDATIVE PHOSPHORYLATION; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ACONITATE HYDRATASE; CELL PROLIFERATION; CITRIC ACID CYCLE; ENERGY METABOLISM; FUMARATE HYDRATASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOCITRATE DEHYDROGENASE; MALATE DEHYDROGENASE; MITOCHONDRIA; MUTATION; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; PROLYL HYDROXYLASES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; SUCCINATE DEHYDROGENASE;

EID: 84920136325     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.02.023     Document Type: Review

References (93)

1. *. Annu. Rev. Genet. 2009, 43:95-118.
2. Owen O.E., Kalhan S.C., Hanson R.W. The key role of anaplerosis and cataplerosis for citric acid cycle function. J. Biol. Chem. 2002, 277:30409-30412.
3. Nunnari J., Suomalainen A. Mitochondria: in sickness and in health. Cell 2012, 148:1145-1159.
4. Brandon M., Baldi P., Wallace D.C. Mitochondrial mutations in cancer. Oncogene 2006, 25:4647-4662.
5. Bournat J.C., Brown C.W. Mitochondrial dysfunction in obesity. Curr. Opin. Endocrinol. Diabetes Obesity 2010, 17:446-452.
6. Wallace D.C., Fan W., Procaccio V. Mitochondrial energetics and therapeutics. Annu. Rev. Pathol. 2010, 5:297-348.
7. Labbe R.F., Kurumada T., Onisawa J. The role of succinyl-CoA synthetase in the control of heme biosynthesis. Biochim. Biophys. Acta 1965, 111:403-415.
8. Hooda J., Cadinu D., Alam M.M., Shah A., Cao T.M., Sullivan L.A., Brekken R., Zhang L. Enhanced heme function and mitochondrial respiration promote the progression of lung cancer cells. PLoS ONE 2013, 8:e63402.
9. Navone N.M., Polo C.F., Frisardi A.L., Andrade N.E., Battle A.M. Heme biosynthesis in human breast cancer-mimetic "in vitro" studies and some heme enzymic activity levels. Int. J. Biochem. 1990, 22:1407-1411.
10. Zheng J. Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (review). Oncol. Lett. 2012, 4:1151-1157.
11. Scott D.A., Richardson A.D., Filipp F.V., Knutzen C.A., Chiang G.G., Ronai Z.A., Osterman A.L., Smith J.W. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J. Biol. Chem. 2011, 286:42626-42634.
12. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
13. Jitrapakdee S., Vidal-Puig A., Wallace J.C. Anaplerotic roles of pyruvate carboxylase in mammalian tissues. Cell. Mol. Life Sci. 2006, 63:843-854.
14. Saini A.G., Singhi P. Infantile metabolic encephalopathy due to fumarase deficiency. J. Child Neurol. 2013, 28:535-537.
15. Guffon N., Lopez-Mediavilla C., Dumoulin R., Mousson B., Godinot C., Carrier H., Collombet J.M., Divry P., Mathieu M., Guibaud P. 2-Ketoglutarate dehydrogenase deficiency, a rare cause of primary hyperlactataemia: report of a new case. J. Inherit. Metab. Dis. 1993, 16:821-830.
16. Carrozzo R., Dionisi-Vici C., Steuerwald U., Lucioli S., Deodato F., Di Giandomenico S., Bertini E., Franke B., Kluijtmans L.A., Meschini M.C., Rizzo C., Piemonte F., Rodenburg R., Santer R., Santorelli F.M., van Rooij A., Vermunt-de Koning D., Morava E., Wevers R.A. SUCLA2 mutations are associated with mild methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness. Brain 2007, 130:862-874.
17. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., Lawrence E.C., Myssiorek D., Bosch A., van der Mey A., Taschner P.E., Rubinstein W.S., Myers E.N., Richard C.W., Cornelisse C.J., Devilee P., Devlin B. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000, 287:848-851.
18. Tomlinson I.P., Alam N.A., Rowan A.J., Barclay E., Jaeger E.E., Kelsell D., Leigh I., Gorman P., Lamlum H., Rahman S., Roylance R.R., Olpin S., Bevan S., Barker K., Hearle N., Houlston R.S., Kiuru M., Lehtonen R., Karhu A., Vilkki S., Laiho P., Eklund C., Vierimaa O., Aittomaki K., Hietala M., Sistonen P., Paetau A., Salovaara R., Herva R., Launonen V., Aaltonen L.A. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 2002, 30:406-410.
19. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., Bigner D.D. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
20. Raimundo N., Baysal B.E., Shadel G.S. Revisiting the TCA cycle: signaling to tumor formation. Trends Mol. Med. 2011, 17:641-649.
21. Krell D., Assoku M., Galloway M., Mulholland P., Tomlinson I., Bardella C. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PLoS ONE 2011, 6:e19868.
22. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
23. Dang L., Jin S., Su S.M. IDH mutations in glioma and acute myeloid leukemia. Trends Mol. Med. 2010, 16:387-397.
24. Kang M.R., Kim M.S., Oh J.E., Kim Y.R., Song S.Y., Seo S.I., Lee J.Y., Yoo N.J., Lee S.H. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer 2009, 125:353-355.
25. Yen K.E., Bittinger M.A., Su S.M., Fantin V.R. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 2010, 29:6409-6417.
26. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
27. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., Cross J.R., Fantin V.R., Hedvat C.V., Perl A.E., Rabinowitz J.D., Carroll M., Su S.M., Sharp K.A., Levine R.L., Thompson C.B. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
28. Bardella C., Pollard P.J., Tomlinson I. SDH mutations in cancer. Biochim. Biophys. Acta 1807, 2011:1432-1443.
29. Niemann S., Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet. 2000, 26:268-270.
30. Astuti D., Douglas F., Lennard T.W., Aligianis I.A., Woodward E.R., Evans D.G., Eng C., Latif F., Maher E.R. Germline SDHD mutation in familial phaeochromocytoma. Lancet 2001, 357:1181-1182.
31. Baysal B.E., Willett-Brozick J.E., Lawrence E.C., Drovdlic C.M., Savul S.A., McLeod D.R., Yee H.A., Brackmann D.E., Slattery W.H., Myers E.N., Ferrell R.E., Rubinstein W.S. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J. Med. Genet. 2002, 39:178-183.
32. Burnichon N., Briere J.J., Libe R., Vescovo L., Riviere J., Tissier F., Jouanno E., Jeunemaitre X., Benit P., Tzagoloff A., Rustin P., Bertherat J., Favier J., Gimenez-Roqueplo A.P. SDHA is a tumor suppressor gene causing paraganglioma. Hum. Mol. Genet. 2010, 19:3011-3020.
33. Vanharanta S., Buchta M., McWhinney S.R., Virta S.K., Peczkowska M., Morrison C.D., Lehtonen R., Januszewicz A., Jarvinen H., Juhola M., Mecklin J.P., Pukkala E., Herva R., Kiuru M., Nupponen N.N., Aaltonen L.A., Neumann H.P., Eng C. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet. 2004, 74:153-159.
34. Baysal B.E. A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia. PLoS ONE 2007, 2:e436.
35. Gottlieb E., Tomlinson I.P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 2005, 5:857-866.
36. Scheffler I.E. Mitochondria 2008, J. Wiley and Sons Inc, Hoboken, New Jersey. second ed.
37. Bayley J.P., Launonen V., Tomlinson I.P. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. BMC Med. Genet. 2008, 9:20.
38. Launonen V., Vierimaa O., Kiuru M., Isola J., Roth S., Pukkala E., Sistonen P., Herva R., Aaltonen L.A. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:3387-3392.
39. Refae M.A., Wong N., Patenaude F., Begin L.R., Foulkes W.D. Hereditary leiomyomatosis and renal cell cancer: an unusual and aggressive form of hereditary renal carcinoma. Nat. Clin. Pract. Oncol. 2007, 4:256-261.
40. Lehtonen H.J. Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Familial Cancer 2011, 10:397-411.
41. Raimundo N., Ahtinen J., Fumic K., Baric I., Remes A.M., Renkonen R., Lapatto R., Suomalainen A. Differential metabolic consequences of fumarate hydratase and respiratory chain defects. Biochim. Biophys. Acta 2008, 1782:287-294.
42. Selak M.A., Armour S.M., MacKenzie E.D., Boulahbel H., Watson D.G., Mansfield K.D., Pan Y., Simon M.C., Thompson C.B., Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7:77-85.
43. Majmundar A.J., Wong W.J., Simon M.C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 2010, 40:294-309.
44. Tanimoto K., Makino Y., Pereira T., Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000, 19:4298-4309.
45. O'Flaherty L., Adam J., Heather L.C., Zhdanov A.V., Chung Y.L., Miranda M.X., Croft J., Olpin S., Clarke K., Pugh C.W., Griffiths J., Papkovsky D., Ashrafian H., Ratcliffe P.J., Pollard P.J. Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism. Hum. Mol. Genet. 2010, 19:3844-3851.
46. Yogev O., Singer E., Shaulian E., Goldberg M., Fox T.D., Pines O. Fumarase: a mitochondrial metabolic enzyme and a cytosolic/nuclear component of the DNA damage response. PLoS Biol. 2010, 8:e1000328.
47. Isaacs J.S., Jung Y.J., Mole D.R., Lee S., Torres-Cabala C., Chung Y.L., Merino M., Trepel J., Zbar B., Toro J., Ratcliffe P.J., Linehan W.M., Neckers L. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005, 8:143-153.
48. Koivunen P., Hirsila M., Remes A.M., Hassinen I.E., Kivirikko K.I., Myllyharju J. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J. Biol. Chem. 2007, 282:4524-4532.
49. Koivunen P., Lee S., Duncan C.G., Lopez G., Lu G., Ramkissoon S., Losman J.A., Joensuu P., Bergmann U., Gross S., Travins J., Weiss S., Looper R., Ligon K.L., Verhaak R.G., Yan H., Kaelin W.G. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012, 483:484-488.
50. Ozer A., Bruick R.K. Non-heme dioxygenases: cellular sensors and regulators jelly rolled into one?. Nat. Chem. Biol. 2007, 3:144-153.
51. Lee S., Nakamura E., Yang H., Wei W., Linggi M.S., Sajan M.P., Farese R.V., Freeman R.S., Carter B.D., Kaelin W.G., Schlisio S. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005, 8:155-167.
52. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H.F., Tallman M.S., Sun Z., Wolniak K., Peeters J.K., Liu W., Choe S.E., Fantin V.R., Paietta E., Lowenberg B., Licht J.D., Godley L.A., Delwel R., Valk P.J., Thompson C.B., Levine R.L., Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
53. Cervera A.M., Bayley J.P., Devilee P., McCreath K.J. Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells. Mol. Cancer 2009, 8:89.
54. Smith E.H., Janknecht R., Maher L.J. Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum. Mol. Genet. 2007, 16:3136-3148.
55. Xiao M., Yang H., Xu W., Ma S., Lin H., Zhu H., Liu L., Liu Y., Yang C., Xu Y., Zhao S., Ye D., Xiong Y., Guan K.L. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012, 26:1326-1338.
56. Toyokuni S., Okamoto K., Yodoi J., Hiai H. Persistent oxidative stress in cancer. FEBS Lett. 1995, 358:1-3.
57. Reitman Z.J., Jin G., Karoly E.D., Spasojevic I., Yang J., Kinzler K.W., He Y., Bigner D.D., Vogelstein B., Yan H. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3270-3275.
58. Franco R., Cidlowski J.A. Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ. 2009, 16:1303-1314.
59. Desideri E., Filomeni G., Ciriolo M.R. Glutathione participates in the modulation of starvation-induced autophagy in carcinoma cells. Autophagy 2012, 8:1769-1781.
60. Filomeni G., Rotilio G., Ciriolo M.R. Disulfide relays and phosphorylative cascades: partners in redox-mediated signaling pathways. Cell Death Differ. 2005, 12:1555-1563.
61. Filomeni G., Desideri E., Cardaci S., Rotilio G., Ciriolo M.R. Under the ROS...thiol network is the principal suspect for autophagy commitment. Autophagy 2010, 6:999-1005.
62. Gilbert M.R., Liu Y., Neltner J., Pu H., Morris A., Sunkara M., Pittman T., Kyprianou N., Horbinski C. Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathol. (Berl.) 2013.
63. Mathew R., Karp C.M., Beaudoin B., Vuong N., Chen G., Chen H.Y., Bray K., Reddy A., Bhanot G., Gelinas C., Dipaola R.S., Karantza-Wadsworth V., White E. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009, 137:1062-1075.
64. Ishii N., Fujii M., Hartman P.S., Tsuda M., Yasuda K., Senoo-Matsuda N., Yanase S., Ayusawa D., Suzuki K. A mutation in succinate dehydrogenase cytochrome b causes oxidative stress and ageing in nematodes. Nature 1998, 394:694-697.
65. Senoo-Matsuda N., Yasuda K., Tsuda M., Ohkubo T., Yoshimura S., Nakazawa H., Hartman P.S., Ishii N. A defect in the cytochrome b large subunit in complex II causes both superoxide anion overproduction and abnormal energy metabolism in caenorhabditis elegans. J. Biol. Chem. 2001, 276:41553-41558.
66. Ishii T., Yasuda K., Akatsuka A., Hino O., Hartman P.S., Ishii N. A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. Cancer Res. 2005, 65:203-209.
67. Adam J., Hatipoglu E., O'Flaherty L., Ternette N., Sahgal N., Lockstone H., Baban D., Nye E., Stamp G.W., Wolhuter K., Stevens M., Fischer R., Carmeliet P., Maxwell P.H., Pugh C.W., Frizzell N., Soga T., Kessler B.M., El-Bahrawy M., Ratcliffe P.J., Pollard P.J. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 2011, 20:524-537.
68. Ooi A., Wong J.C., Petillo D., Roossien D., Perrier-Trudova V., Whitten D., Min B.W., Tan M.H., Zhang Z., Yang X.J., Zhou M., Gardie B., Molinie V., Richard S., Tan P.H., Teh B.T., Furge K.A. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 2011, 20:511-523.
69. Schafer F.Q., Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radical Biol. Med. 2001, 30:1191-1212.
70. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., Qian D., Lam J.S., Ailles L.E., Wong M., Joshua B., Kaplan M.J., Wapnir I., Dirbas F.M., Somlo G., Garberoglio C., Paz B., Shen J., Lau S.K., Quake S.R., Brown J.M., Weissman I.L., Clarke M.F. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
71. Ishimoto T., Nagano O., Yae T., Tamada M., Motohara T., Oshima H., Oshima M., Ikeda T., Asaba R., Yagi H., Masuko T., Shimizu T., Ishikawa T., Kai K., Takahashi E., Imamura Y., Baba Y., Ohmura M., Suematsu M., Baba H., Saya H. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer cell 2011, 19:387-400.
72. Olivier M., Hollstein M., Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2010, 2:a001008.
73. Muller P.A., Vousden K.H. P53 mutations in cancer. Nat. Cell Biol. 2013, 15:2-8.
74. Jiang P., Du W., Mancuso A., Wellen K.E., Yang X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 2013, 493:689-693.
75. Wasilenko W.J., Marchok A.C. Malic enzyme and malate dehydrogenase activities in rat tracheal epithelial cells during the progression of neoplasia. Cancer Lett. 1985, 28:35-42.
76. Sauer L.A., Dauchy R.T., Nagel W.O., Morris H.P. Mitochondrial malic enzymes. Mitochondrial NAD(P)+-dependent malic enzyme activity and malate-dependent pyruvate formation are progression-linked in Morris hepatomas. J. Biol. Chem. 1980, 255:3844-3848.
77. Singh K.K., Desouki M.M., Franklin R.B., Costello L.C. Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol. Cancer 2006, 5:14.
78. Tsui K.H., Feng T.H., Lin Y.F., Chang P.L., Juang H.H. P53 downregulates the gene expression of mitochondrial aconitase in human prostate carcinoma cells. Prostate 2011, 71:62-70.
79. Ternette N., Yang M., Laroyia M., Kitagawa M., O'Flaherty L., Wolhulter K., Igarashi K., Saito K., Kato K., Fischer R., Berquand A., Kessler B.M., Lappin T., Frizzell N., Soga T., Adam J., Pollard P.J. Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Rep. 2013, 3:689-700.
80. Wang P., Mai C., Wei Y.L., Zhao J.J., Hu Y.M., Zeng Z.L., Yang J., Lu W.H., Xu R.H., Huang P. Decreased expression of the mitochondrial metabolic enzyme aconitase (ACO2) is associated with poor prognosis in gastric cancer. Med. Oncol. 2013, 30:552.
81. Chan S.Y., Zhang Y.Y., Hemann C., Mahoney C.E., Zweier J.L., Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. 2009, 10:273-284.
82. Rothe F., Ignatiadis M., Chaboteaux C., Haibe-Kains B., Kheddoumi N., Majjaj S., Badran B., Fayyad-Kazan H., Desmedt C., Harris A.L., Piccart M., Sotiriou C. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS ONE 2011, 6:e20980.
83. Santos C.R., Schulze A. Lipid metabolism in cancer. FEBS J. 2012, 279:2610-2623.
84. Hatzivassiliou G., Zhao F., Bauer D.E., Andreadis C., Shaw A.N., Dhanak D., Hingorani S.R., Tuveson D.A., Thompson C.B. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005, 8:311-321.
85. Catalina-Rodriguez O., Kolukula V.K., Tomita Y., Preet A., Palmieri F., Wellstein A., Byers S., Giaccia A.J., Glasgow E., Albanese C., Avantaggiati M.L. The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget 2012, 3:1220-1235.
86. Hanai J.I., Doro N., Seth P., Sukhatme V.P. ATP citrate lyase knockdown impacts cancer stem cells in vitro. Cell Death Dis. 2013, 4:e696.
87. Ning X., Shu J., Du Y., Ben Q., Li Z. Therapeutic strategies targeting cancer stem cells. Cancer Biol. Ther. 2013, 14:295-303.
88. Pouyssegur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
89. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3:177-185.
90. Fujiwara S., Kawano Y., Yuki H., Okuno Y., Nosaka K., Mitsuya H., Hata H. PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br. J. Cancer 2013, 108:170-178.
91. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
92. Gao P., Tchernyshyov I., Chang T.C., Lee Y.S., Kita K., Ochi T., Zeller K.I., De Marzo A.M., Van Eyk J.E., Mendell J.T., Dang C.V. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009, 458:762-765.
93. Wise D.R., Thompson C.B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 2010, 35:427-433.